Table of contents
Pharmaceutical supply chain leaders are racing to deploy AI across their operations. Yet most still rely on fragmented data, manual coordination with partners, and disconnected systems.
The result: 65% of supply chain leaders express limited confidence in AI’s ability to predict or mitigate disruption across pharmaceutical supply chains.
The challenge is not AI innovation. It is building the digital foundation required to operationalize AI across complex, multi-enterprise supply networks.
Download the LogiPharma Playbook: 2026 Supply Chain & Logistics Insights to explore the latest research on how life sciences leaders are advancing supply chain digitalization and AI adoption—and what it will take to move from experimentation to end-to-end agentic orchestration across regulated global networks.
The report combines industry survey data with perspectives from leading supply chain experts, including Shabbir Dahod, President & CEO of TraceLink.
What You’ll Learn
- Where pharmaceutical companies are actually deploying AI today—and why demand planning (59%), inventory optimization (57%), and logistics orchestration (49%) are emerging as the first proving grounds.
- The digital maturity advantage: why the most connected supply chains are achieving 15% lower logistics costs, 35% lower inventory, and 65% higher service levels.
- The real barriers slowing AI adoption in regulated supply chains—from cybersecurity and compliance concerns to fragmented partner ecosystems.
- What it takes to move beyond AI experimentation and build the digital foundation for real-time, multi-enterprise supply chain execution.
Download the report now to see how pharmaceutical supply chain leaders are preparing their organizations for the next generation of intelligent supply chain operations.
